Prediction of disease-free survival after therapy in Wilms' tumor using nuclear morphometric techniques
- PMID: 8201520
- DOI: 10.1016/0022-3468(94)90592-4
Prediction of disease-free survival after therapy in Wilms' tumor using nuclear morphometric techniques
Abstract
The outlook for children with Wilms' tumor has markedly improved with the use of multimodal therapy, and survival currently exceed 85%. Current trends have been to use less intense therapy for children whose tumors have favorable histology (FH). By decreasing the amount of therapy given to patients whose conditions have an excellent chance of responding, the need for accurate criteria to separate high-risk and low-risk groups becomes imperative. Nuclear morphometric techniques have been developed and extensively tested in the author's laboratory. Preliminary studies of FH Wilms' tumors demonstrated the applicability of this technique. Herein, the authors present a retrospective study of 108 patients with FH tumors, with a mean follow-up period of 1,994 +/- 107 days (66 months) for those whose tumors did respond to therapy, and 686 +/- 61 days (23 months) for those whose tumors did not respond. The univariate predictors were age (P = .02), the skewness of nuclear roundness factor (SNRF) (P = .009), and the mean of the lower five values for nuclear ellipticity, measured by the feret diameter method (L5EFD) (P = .01). A multivariate analysis combining all three variables better separated the two groups (P = .00016). A probability function curve was constructed to predict poor prognosis. Kaplan-Meier actuarial survival analysis was used to predict disease-free survival as clinical progression, and separated the two groups (P = .0004, Wilcoxon-Gehan statistic). These results suggest that nuclear morphometry is useful in the initial assessment of patients with Wilms' tumor.
Similar articles
-
Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation.J Clin Oncol. 1999 Jul;17(7):2123-6. doi: 10.1200/JCO.1999.17.7.2123. J Clin Oncol. 1999. PMID: 10561267
-
The use of nuclear morphometry to predict response to therapy in Wilms' tumor.Cancer. 1992 Feb 1;69(3):804-8. doi: 10.1002/1097-0142(19920201)69:3<804::aid-cncr2820690332>3.0.co;2-7. Cancer. 1992. PMID: 1309682
-
Nuclear morphometric analysis of metastasis in Wilms' tumor after multimodal therapy: comparison with primary tumor.Urology. 1995 Jan;45(1):119-23. doi: 10.1016/s0090-4295(95)97318-4. Urology. 1995. PMID: 7817463
-
Wilms' tumor: diagnosis and treatment in the 1990s.Semin Pediatr Surg. 1993 Feb;2(1):59-68. Semin Pediatr Surg. 1993. PMID: 8062023 Review.
-
Wilms' tumor: past, present and (possibly) future.Expert Rev Anticancer Ther. 2006 Feb;6(2):249-58. doi: 10.1586/14737140.6.2.249. Expert Rev Anticancer Ther. 2006. PMID: 16445377 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous